Join us for our half-day conference, ‘Beyond the Pandemic: The Impact of the COVID-19 Research Response in Low- and Middle-Income Countries’, 13 December 2022.
Apply for funding to establish a large-scale research hub to address challenges relating to vaccine delivery or manufacturing in low and middle income countries.
Learn step-by-step how we work with data to make the most comprehensive database on COVID-19 research funding.
Apply for funding to generate robust new scientific evidence that will improve health outcomes for people in low resource settings through improving practice and informing policy.
Are you a talented early-career scientist who has already produced excellent supervised work, is ready to work independently and shows potential to be a research...
Apply for funding to support excellent global health research and strengthen research leadership across sub-Saharan Africa.
Welcoming and encouraging applications from individuals based in LMICs, these programmes provide funding to support not only delivery of research but also strengthen crucial research capability and capacity in resource-poor settings, including training and capacity-strengthening in both academic research and programme support functions.
This blog series, ‘Equitable Partnerships: Lessons from Practitioners’, explores the importance of equity, as well as its barriers and enablers. Each blog provides best practices and learning examples informed by their experience in the field.
To make best use of the expansive data in the COVID-19 Research Project Tracker, UKCDR & GloPID-R have produced a Living Mapping Review of COVID-19 funded research projects, which analyses globally funded COVID-19 related research.
As the COVID-19 global research funding response has hit a plateau, the Living Mapping Review (LMR) continues to provide valuable information for the international community of researchers and funders. The latest and sixth iteration of the LMR is the first to include an in-depth analysis of existing research into new COVID-19 variants.